Prosonix, an emerging pharmaceutical company developing a portfolio of enhanced respiratory medicines enabled by its novel proprietary particle engineering technology, today announces the appointment of a new Scientific Advisory Board. The new SAB comprises internationally renowned scientific, regulatory and clinical advisors who will act as both as key collaborators and advocates for the business in the global pharmaceutical arena.
The SAB will be chaired by Dr Ken Cunningham, who recently joined Prosonix’ board as a Non-executive Director. He brings over 20 years’ experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery.
In addition to Dr Cunningham, the inaugural members of Prosonix’ SAB include:
Professor Peter Barnes
Professor Barnes is Professor of Thoracic Medicine and Head of Airway Disease at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London. He is amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the past 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest and respiratory Editor of PLoS Medicine.
Dr Marianne Mann
Dr Mann is a board-certified pulmonologist and independent consultant specialising in regulatory and clinical drug development, with specific interest in respiratory diseases. She worked at the US Food and Drug Administration (FDA) for nine years, between 1994 and 2003, the last three of which were as Deputy Director of the Division of Pulmonary and Allergy Drug Products.
Dr John Pritchard
Dr Pritchard is Chief Technology Officer at Philips’ Respironics drug delivery unit. In this role, he is responsible for global R&D activities in respiratory drug delivery, focusing on next-generation adaptive aerosol delivery technology. Dr Pritchard has over 30 years of experience in the aerosol and respiratory field, including experience at AstraZeneca as head of respiratory project management. He has also worked for 3M Healthcare and GlaxoSmithKline.
Commenting on the new SAB, David Hipkiss, Prosonix’ CEO, said: “The formation of our first formal Scientific Advisory Board is a significant step for Prosonix, signalling our strong intent to build on our past successes and advance the development of our pipeline of respiratory drug candidates into the clinic and towards regulatory approval. In particular, the next 12 months will see the Company prepare to file PSX1001 in Europe for asthma based on strong in vitro bioequivalence data, being potentially the first company to do so. The Company also plans to launch a Phase II proof of concept clinical study with PSX1002 in COPD and to initiate the development of our first PSX2000 combination therapy for respiratory diseases based on our unique UMAX® Multi-Component Particle (MCPTM) platform. We are therefore delighted to announce the new members of our SAB, all of whom are distinguished experts in their relevant fields and will provide invaluable advice and guidance to the Company during this exciting period.”